https://www.selleckchem.com/products/od36.html
Recent advances in the treatment of breast cancer (BC) have been related to the personalization of therapy. The methylation status of the promoter regions of tumor suppressor genes such as BRCA1and BRCA2is supposed to be useful as a prognostic factor in BC patients. To investigate the frequency of hypermethylation in the promoter regions of BRCA1and BRCA2genes in tumor tissue of BC patients, and the relation of hypermethylation to the clinical course of the disease. Molecular genetic studies were performed on 50BC tissue samples in order t
إعجاب
علق
شارك
